DEVELOPING A TUBERCULOSIS PROTOCOL MANUAL FOR THE SALINE COUNTY HEALTH DEPARTMENT

JONATHAN YANG
MPH CANDIDATE
2017
Table of Contents

- **Chapter 1**: Scope of Work
- **Chapter 2**: Objectives, Activities, & Products
- **Chapter 3**: Developing a Tuberculosis Protocol Manual for the Saline County Health Department
Chapter 1: Scope of Work

Saline County Health Department (SCHD)
Mentor: Jason Tiller, M.S. (Director, SCHD)

Population (Saline County): ~55,000

Cities Served: Assaria, Brookville, Gypsum, New Cambria, Salina, Smolan, Solomon (partly in Dickinson County)

Departments (SCHD): 1) WIC, 2) MCH, 3) Home Health, 4) Child Care Licensing, 5) Health Education, 6) Nursing Clinic, 7) PHEP
Scope of Work:

- Become familiar with all aspects of a local health department
- Enrich knowledge of public health and infectious disease/zoonoses
Chapter 2: Objectives, Activities, & Products

Learning Objectives, Activities Performed, & Products Developed
Learning Objectives and Activities Performed:

- Became better acquainted with different aspects of public health by attending meetings and conferences.

- Learned about how the different branches of a health department work together to improve the health of the community it serves.

- Broadened knowledge pertaining to infectious diseases/zoonoses while working on tuberculosis protocol.
Meetings

- “LiveWell Saline County” Meeting
- "Kansas Healthy Living” Meeting
- “Central KS Region for Public Health Emergency Preparedness” Meeting
- "Becoming a Mom" Session
Conference: KALHD (Kansas Association of Local Health Departments)

Lectures:
- Bioinformatics
- Public Health 3.0
- Effective Health Communication
Saline County Health Department Staff

(Director, WIC, MCH, Home Health, Child Care Licensing, Health Education, Clinic Services, PHEP)
Director (Jason Tiller, M.S.)

- Oversees health department branches
- Meets with Advisory Council
- Works with Finance Department to ensure grants/funding
- “Wears many hats”
1) Women, Infants, & Children (WIC)

- Offers nutrition support:
  - Pregnant women
  - Breastfeeding women
  - Postpartum women
  - Children up to 5 years of age
- Prevent or correct health problems caused by poor nutrition
- Free to qualifying parents/legal guardians
2) Maternal and Child Health (MCH)

- Special Health Care Needs (SHCN)
- Maternal & Infant Program (M&I)
- Becoming a Mom
- Maternal & Child Health (MCH)
  Home Visitor Program
- Breastfeeding Coalition
3) Home Health

- Medicare certified & Kansas State Licensed Agency
- Provides intermittent professional home health care
- RN on call 24 hours a day
- Patients receiving home health:
  - A recent hospitalization
  - Outpatient surgery
  - A temporary or long-term disability
  - A chronic illness
  - Aging
  - Special needs
4) Child Care Licensing

- Inspects (for 3 counties- Saline, Ottawa, & McPherson)
  - Family child care homes
  - Preschools
  - Child care centers
  - School age facilities
- Protecting the health, safety, and welfare of children receiving care away from their parents
5) Health Education

- Chronic and Infectious Disease Prevention
- Why Wellness?
- Tobacco Use Prevention
- Pictured: HYPE (Helping Youth Pursue Excellence)
6) Clinic Services

- Family Planning Services
- Pregnancy Testing
- STI Testing
- Immunizations
- Foreign Travel Immunizations
- Communicable Disease Prevention
- TB Testing & Treatment
- Lead Poisoning Prevention
- HIV/AIDS Case Management
7) Public Health Emergency Preparedness (PHEP)

- Central KS Region for Public Health Emergency Preparedness Meeting
- Disaster Preparation
  - Earthquakes
  - Floods
  - Tornados
  - Infectious Disease Outbreaks
Product Developed:

- Saline County Health Department Guidelines for the Prevention, Diagnosis, and Treatment of Tuberculosis (2017)

(written for use by the Saline County Health Department and other local health departments in Kansas)
Chapter 3: Developing a Tuberculosis Protocol Manual for the SCHD

*MPH Competencies*

3.1) Introduction
3.2) Methods
3.3) Results/Discussion
MPH Competencies

1) BIOSTATISTICS
2) ENVIRONMENTAL HEALTH SCIENCES
3) EPIDEMIOLOGY
4) HEALTH SERVICES ADMINISTRATION
5) SOCIAL AND BEHAVIORAL SCIENCES
3.1) Introduction

3.1.1) DISCUSSING NEEDS OF THE SCHD
3.1.2) CAPSTONE PROJECT OBJECTIVE
3.1.1) Discussing Needs of the SCHD:

- Communicable Disease / TB Program Manager
  - Maria Shoulty's, RN

- Kansas Department of Health and Environment (KDHE)
  - Currently has a TB control program and offers helpful links on webpage
  - Does not offer a standard TB protocol
3.1.2) Capstone Project Objective:

- Create a comprehensive and accurate TB protocol manual that is customized for health care workers treating TB in Kansas as well as any underserved Kansan subpopulations.
3.2) Methods

3.2.1) QUALITATIVE RESEARCH
3.2.2) RESEARCH QUESTION
3.2.3) QUANTITATIVE RESEARCH
3.2.4) PRODUCING THE PRODUCT
3.2.5) EXTERNAL REVIEW
3.2.1) Qualitative Research:

- Tuberculosis Literature Review
- Review of TB Protocol Manuals from Other States
- Economic Impacts of TB Treatment
- CDC-Recommended Guidelines for TB Management/Control

- MPH Competency (Epidemiology):
  - Epidemiological triad
    - Host, Agent, & Environment
  - Epitrax
    - Electronic disease surveillance system for Kansas
Mycobacterium tuberculosis
TB – Background

► Agent
  ► *Mycobacterium tuberculosis*
  ► *M. Africanum, M. bovis, M. microti, etc*\(^{(30)}\)

► Discovery
  ► German microbiologist, Robert Koch
    ► Discovered microbial cause of TB in 1882

► Impact
  ► ~9 million people get sick with TB
  ► ~2 million lives are claimed yearly – WHO\(^{(4)}\)
TB – Transmission

- **Primary mode of transmission**
  - Airborne (droplet nuclei) particles
    - Expelled (via coughing, sneezing, etc.) by a person with infectious, or active TB

- **Size & Hardiness**
  - 1-5 microns in diameter
  - Depending on the environment, may remain suspended in the air for hours
TB transmission probability directly increases with an increase in:

- **Susceptibility**
  - Of exposed individual

- **Infectiousness**
  - Of the person with TB disease

- **Environmental factors**
  - That affect the concentration of *M. tuberculosis* organisms

- **Level of exposure**
  - E.g. Proximity, frequency, & duration of exposure to the infected individual\(^{(30)}\)
TB – Prevention/Management

- **Stopping transmission of TB**
  - Promptly identifying and isolating patients with infectious TB and starting appropriate treatment
    - The level of infectiousness will decrease with treatment

- **Directly Observed Therapy (DOT)**
  - Health care worker physically observing a TB patient ingest his or her medication
TB – Pathogenesis

- Person ingests air with droplet nuclei containing tubercle bacilli
- Alveolar macrophages ingest tubercle bacilli
  - Intracellular replication
    - Bacilli released with macrophage death
      - Lymphatic channels → regional lymph nodes
      - Bloodstream → other locations
        - E.g. kidneys, brain, and bone
      - Most cases → remains localized
        - Apices of the lungs

\(^{30}\)
LTBI vs. Active TB

- **Latent TB Infection (LTBI)**
  - Infected with TB bacilli
  - *Asymptomatic* and not contagious
  - Returns a positive reaction on the tuberculin skin test (TST)

- **Active TB Disease**
  - Without treatment, 5 to 10% of those with LTBI eventually develop active TB disease
  - Characterized by *morbidity, contagiousness, and indicative chest x-ray (CXR)* findings or positive TB diagnostic tests
  - Immunocompromised individuals (e.g. HIV/AIDS patients)
    - Have a higher risk of developing active TB disease\(^{(29)}\)
<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Duration</th>
<th>Drug(s and Dosages)</th>
<th>Interval</th>
<th>Doses</th>
</tr>
</thead>
</table>
| **Isoniazid (INH)** | 9 months | Adult: 5 mg/kg  
Children: 10-20 mg/kg**  
Max dose: 300 mg  
Adults: 15 mg/kg  
Children: 20-40 mg/kg**  
Max dose: 900 mg  
**Twice weekly DOT (Directly Observed Therapy)** | Daily               | 270    |
|                     | 6 months | Adult: 5 mg/kg  
Children: NOT RECOMMENDED  
Max dose: 300 mg  
Adults: 15 mg/kg  
Children: NOT RECOMMENDED  
Max dose: 900 mg  
**Twice weekly DOT (Directly Observed Therapy)** | Daily               | 180    |
| **Isoniazid (INH) & Rifapentine (RPT)** | 3 months | Adult & Children (12+ Years):  
INH*: 15 mg/kg rounded up to nearest 50 or 100 mg  
Max dose: 900 mg  
RPT* (by weight):  
10.0-14.0 kg → 300 mg  
14.1-25.0 kg → 450 mg  
25.1-32.0 kg → 600 mg  
32.1-49.9 kg → 750 mg  
≥50.0 kg → 900 mg (Max dose)  
**Once weekly DOT (Directly Observed Therapy)** | 12                  |
| **Rifampin (RIF)** | 4 months | Adult: 10 mg/kg***  
Max dose: 600 mg | Daily               | 120    |

* INH is formulated as 100 & 300 mg tablets. RPT is formulated as 150 mg tablets in packs that should be kept sealed until usage.
** The American Academy of Pediatrics recommends an INH dosage of 10-15 mg/kg for daily regimen and 20-30 mg/kg for the twice weekly regimen.
*** The recommended regimen for LTBI treatment in children is a 9-month course of INH. For LTBI treatment in infants, children, and adolescents with INH intolerance or a child with contact with a patient infected with an INH-resistant but rifampin-susceptible organism, the American Academy of Pediatrics recommends 6 months of daily Rif (180 doses) at a dosage of 10-20 mg/kg.

Table 4: Latent TB Infection Treatment Regimens(32)
### STANDARD DRUG-SUSCEPTIBLE TB DISEASE TREATMENT REGIMENS

#### INITIAL Phase (2-5 Weeks)

<table>
<thead>
<tr>
<th>REGIMEN &amp; DRUGS</th>
<th>INTERVAL/DOSAGE MODIFICATION</th>
<th>REGIMEN &amp; DRUGS</th>
<th>INTERVAL/DOSAGE MODIFICATION</th>
<th>TOTAL (DOSIS)</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) INH, Rif*, PZA, EMG**</td>
<td>7 days/week for 56 doses (8 weeks) OR 5 days/week for 40 doses (6 weeks)**</td>
<td>(1) INH, Rif</td>
<td>7 days/week for 120 doses (18 weeks) OR 5 days/week for 96 doses (18 weeks)</td>
<td>150-182</td>
<td>Preferred regimen for patients with newly diagnosed Pulmonary TB. Also effective against intestinal TB.</td>
</tr>
<tr>
<td>(2) INH, Rif*, PZA, EMG**</td>
<td>7 days/week for 36 doses (5 weeks) OR 5 days/week for 40 doses (6 weeks)</td>
<td>(2) INH, Rif</td>
<td>7 days/week for 54 doses (8 weeks)</td>
<td>74-110</td>
<td>Preferred regimen in situations in which frequent DTT during continuation phase prevents side effects.</td>
</tr>
<tr>
<td>(3) INH, Rif*, PZA, EMG**</td>
<td>3 times weekly for 24 doses (8 weeks)</td>
<td>(3) INH</td>
<td>3 times weekly for 54 doses (8 weeks)</td>
<td>78</td>
<td>The regimen length can be reduced to 6-8 weeks in patients who are non-compliant. More treatment is required if relapse or treatment failure occurs.</td>
</tr>
<tr>
<td>(4) INH, Rif*, PZA, EMG**</td>
<td>7 days/week for 14 doses, then twice weekly for 12 doses</td>
<td>(4) INH, Rif</td>
<td>Twice weekly for 54 doses (18 weeks)</td>
<td>62</td>
<td>In therapy for drug-resistant strains in patients with positive [tuberculin test] and/or culture for drugs.</td>
</tr>
</tbody>
</table>

* HIV-infected patients on certain antiretroviral drugs may need induction adjustment because of drug interactions with rifampin. ** DTT should be administered daily for the first 6 weeks and daily or three times weekly for the remaining 18 weeks. *** INH can be discontinued prior to the start of continuation phase only if sensitivity to INH, Rif, PZA & EMG is known. **** All regimens (1x, 2x, 3x, and 5x/week) must be administered via DOT (Directly Observed Therapy). 

#### SELECTED DRUGS DOSAGE (MAXIMUM DOSE IN PARENTHESIS)

<table>
<thead>
<tr>
<th>DRUGS</th>
<th>DAILY</th>
<th>WEEKLY</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHILD</td>
<td>ADULT</td>
<td>CHILD</td>
</tr>
<tr>
<td>INH</td>
<td>10-15 mg/kg</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>Rif</td>
<td>10-20 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>PZA*</td>
<td>10-20 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>EMR*</td>
<td>20-40 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>RFT</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### MAXIMUM TB TREATMENT DURATION BY CASE CHARACTERISTICS

<table>
<thead>
<tr>
<th>TB Disease Type</th>
<th>Minimum Weeks of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-resistant TB disease</td>
<td>12</td>
</tr>
<tr>
<td>Culture-negative (non-smear) pulmonary disease</td>
<td>8</td>
</tr>
<tr>
<td>TB meningitis</td>
<td>12</td>
</tr>
<tr>
<td>Without INH</td>
<td>8</td>
</tr>
<tr>
<td>Without PZA (pregnancy &amp; N toxic)</td>
<td>8</td>
</tr>
<tr>
<td>Without Rif</td>
<td>8</td>
</tr>
<tr>
<td>Without INH, Rif &amp; other drugs</td>
<td>16-24</td>
</tr>
<tr>
<td>Contact Chest 6-months Culture-negative 10-12 months</td>
<td>12</td>
</tr>
<tr>
<td>Extrasputum</td>
<td>8</td>
</tr>
<tr>
<td>UN</td>
<td>8</td>
</tr>
<tr>
<td>HIV</td>
<td>8</td>
</tr>
<tr>
<td>Others</td>
<td>8</td>
</tr>
</tbody>
</table>

### Active TB Treatment

Table 7: First-Line TB Drug Dosage (Maximum Dose in Parenthesis)[8, 17]
Multi-Drug Resistant TB

- **Multi-Drug Resistant TB (MDR-TB)**
  - Resistant to:
    - *At least isoniazid and rifampin* (two most potent TB drugs)

- **Extensively Drug Resistant TB (XDR-TB)**
  - Resistant to:
    - *Isoniazid and rifampin*
    - *And any fluoroquinolone*
    - *And at least one of three injectable second-line drugs* (e.g. amikacin, kanamycin, or capreomycin)

- **High chance of developing TB disease**
- **High mortality rates**

(16)
Contact Investigations

- **Who is a Contact?**
  - Anyone who has been exposed to someone with infectious TB
  - *Measuring level of exposure: Duration, proximity, and intensity of shared time*

- **Contact Investigations**
  - Interviewing TB patient and visiting locations where patient spent time
  - Identify/screen contacts & find source or environmental factors

- **The health department is legally responsible for:**
  - Identifying and evaluating contacts
  - Offering treatment to any infected contacts
  - Monitoring adherence to prescribed regimens
  - Ensuring accessibility to completion of treatment
Infection Control

AIRBORNE INFECTION ISOLATION (AII)

1. All should be initiated for all hospitalized TB suspects
   - Until a thorough medical evaluation is conducted
2. TB patient should remain in isolation if infectious
   - Until the treatment renders the patient noninfectious
3. Facilities without an AII room
   - Should have a written plan for referring patients to an equipped facility

All Discontinuation

TB patients may be discontinued from AII when they meet at least one of the following criteria:
1. Another diagnosis assigned
2. 3 consecutive, negative AFB smears
3. At least 2 weeks of treatment with a known, strain-susceptible TB treatment regimen
Infection Control (Continued)

- MPH Competency (Environmental Health Sciences):
  - Unique KS Infection Control Requirements for:
    - 1) Adult care homes
    - 2) Correctional/detention facilities
    - 3) Hospital-based care settings
  - Central Kansas PHEP meeting in Lyons, KS
    - Health directors from 5 different counties
      - Purchasing certain Personal Protective Equipment (PPE)
      - Expired PPE that could no longer serve its purpose
      - Medical waste

Health directors from 5 different counties purchasing certain Personal Protective Equipment (PPE) and addressing expired PPE that could no longer serve its purpose. Medical waste is also a concern.
Review of TB Protocol Manuals from Other States

Four Manuals Referenced:
1. Nebraska Department of Health and Human Services
2. Maryland Department of Health and Hygiene
3. Washington State Department of Health
4. County of Los Angeles Tuberculosis Control Program
# Review of TB Protocol Manuals from Other States

## Table 1. Comparison of Pros & Cons for TB Manuals for Nebraska & Maryland

<table>
<thead>
<tr>
<th></th>
<th>Nebraska</th>
<th>Cons:</th>
<th>Maryland</th>
<th>Cons:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pros:</strong></td>
<td>Logical order of presentation.</td>
<td>No graphics, figures, tables, or cover page.</td>
<td>Some graphics and includes cover page.</td>
<td>No Tuberculin Skin Test instructions.</td>
</tr>
<tr>
<td></td>
<td>Includes very detailed TB Skin Test instructions.</td>
<td>Some aspects are not explained in enough detail (e.g. “Treatment of TB” section had little to no explanation.)</td>
<td>Very thorough and includes a logical order of presentation that is easy to follow.</td>
<td>Some of the guidelines are too study-focused instead of practice-focused. Not ideal for a health care worker to follow and implement.</td>
</tr>
<tr>
<td></td>
<td>Brevity of Information where it is needed.</td>
<td>Small font and no distinguishable spacing between the sections.</td>
<td>Includes many customizable factors that relate to Maryland.</td>
<td>No graphics to help in understanding certain procedures.</td>
</tr>
</tbody>
</table>
Upon Review:

- Emphasis on brevity without compromising content
- CDC-based instructions and graphics
  - Tuberculin Skin Test procedure
- Logical order for the different parts of the CDC manual
  1) Introduction to TB
  2) Latent TB Infection Management
  3) Active TB Management
  4) Adherence Promoting Strategies
  5) Contact Investigations / Infection Control
  6) References and Appendices
Shadowing Experience (Extrapulmonary TB Case Treatment)

- **Extrapulmonary TB Case Management**
  - Observe the process of treating an elderly patient with extrapulmonary tuberculosis
    - Managed every day
    - Travelled to patient’s house daily to provide DOT
  - **Total time (including travel): ~30 minutes**
Economic Impacts of TB Treatment

- The treatment of TB is mostly covered by the public sector.
- Total monthly costs of treating a LTBI case were as follows:
  - 9H: $26.37
  - 9H-DOT: $204.56
  - 3HP (with DOT): $167.82
  - 4R: $53.07
- Toxicity costs, which included lab monitoring: $158.36
- 7-day hospitalization average cost estimate: $5,320.77
  - Range: $4250-$8000 –American Thoracic Society\(^{(58)}\)
Economic Impacts of TB Treatment (Continued)

- **Active TB** case management costs:
  - 6-month treatment regimen, total cost average: $12,511.71
  - 9-month treatment regimen, total cost average: $13,246.57

- **Drug Resistant TB** direct costs of treatment –CDC\(^{(58)}\):
  - Per MDR-TB patient: $134,000
  - Per XDR-TB patient: $430,000

- **MPH Competency (Health Services Administration):**
  - Costs of TB treatment
    - “Managing Non-Adherence”
    - State ordinances (Kansas State Statutes)
  - Obtaining Grants and Grant Allocation
    - Community Health Assessments
    - Need-based reports for grants to support effective health outcomes

Blue Cross Blue Shield (Breakdown of Healthcare Spending)
CDC-Recommended Guidelines for TB Management/Control

- **CDC Website**
  - https://www.cdc.gov/tb

- **Electronic Directly Observed Therapy (e-DOT)**
  - Remote administration of DOT via use of electronic video-sharing devices
3.2.2) Research Question

- What are the specific needs of Saline County or Kansas local health departments as it relates to TB management and control?
3.2.3) Quantitative Research

- KS Active TB Case Data (2012-2017)
  - Demographic & Risk Factor Visualizations
- CDC WONDER Active TB Case Data (1993-2015)
  - Question Formulations
  - Testing of Questions
  - Results, Conclusions, and Discussion
- Additional Data Collection Via SurveyMonkey
  - e-DOT
  - Google Translate
- MPH Competency (Biostatistics):
  - Descriptive and inferential statistical methods
  - Hypothesis Testing / Odds Ratio Calculations
  - Statistical analysis tools: SAS / R
KS Active TB Case Data (2012-2017)

- 167 Case files (Doctor’s Notes) for all Kansan active TB cases from 2012-2017
- Demographic information
- Risk factors
- Visualization
- Package ‘ggplot2’ in R

### Risk Factors for Targeted Testing in Adults & Children/Adolescents

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td></td>
</tr>
<tr>
<td>Foreign-Born from / Recent-Traveler to High-Prevalence Countries (e.g., Mexico, the Philippines, Vietnam, India, China, Haiti, etc.) (\text{See List of HBCs in Appendix B})</td>
<td></td>
</tr>
<tr>
<td>Close Contact with Someone with Infections TB Disease</td>
<td></td>
</tr>
<tr>
<td>Resident/Employee of High-Risk Congregate Setting in Places at High Risk for TB Transmission (e.g., Long-Term Care Facility, Correctional Facility, Hospital, Homeless Shelter)</td>
<td></td>
</tr>
<tr>
<td>The Immunosuppressed: HIV Patients, Organ Transplant Recipients, Substance Abusers (e.g., Smoking, Alcohol Abuse, Injection Drug Use), and those with Secondary Immunosuppression Due to Prednisone Usage (≥ 15 mg/day for One Month) or TNF-α antagonists</td>
<td></td>
</tr>
<tr>
<td>Medical Conditions Associated with Risk of Progressing to TB Disease if Infected (e.g., Diabetes Mellitus, Sarcoidosis, Cancer (Head &amp; Neck), Hodgkin’s Disease, Leukemia, End-Stage Renal Dx, Interstitial Bypass/Gastrectomy, Chronic Malabsorption Syndrome, &amp; Low Body Weight)</td>
<td></td>
</tr>
<tr>
<td>Chest Radiographs with Fibrotic Changes Suggesting Inactive or Past TB</td>
<td></td>
</tr>
<tr>
<td>Signs and Symptoms of TB Disease</td>
<td></td>
</tr>
<tr>
<td>Children ≤ 5 Years Old</td>
<td></td>
</tr>
<tr>
<td>Annual Testing for: HIV-Infected Children and Incarcerated Adults</td>
<td></td>
</tr>
<tr>
<td>Testing Every 2-3 Years for: Children Exposed to HIV-Infected, Homeless, Nursing Home Residents, Institutionalized, Illicit-Drug Users, Incarcerated, or Migrant Farm Workers, &amp; Foster Children Exposed to Adults in Above Categories</td>
<td></td>
</tr>
<tr>
<td>Testing Consideration at 4-6 and 11-16 Years of Age for: Children whose Parents or Household Contacts (w/ Unknown TST Status) Immigrated from High-Prevalence Countries &amp; Children with Continued Potential Exposure by Travel to these Countries</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Risk Factors for Targeted Testing in Adults & Children/Adolescents

\(^{14, 26, 46}\)
Year

- NOTE: 2017 is half-year
- Observed hike in 2013
- Steady drop in concurrent years
Age Distribution

- Age range appears to be fairly uniformly distributed
- Upon age group stratification, distribution may appear to be normally distributed
Ethnicity, Gender, & Ethnicity by Gender

- Ethnicity
  - Asian
  - White
  - Hispanic
  - Black
  - Native American

- Gender
  - Roughly 2 in 3 cases of active TB are male
Country of Birth

- Top 3:
  - USA
  - Mexico
  - India

- Other Countries:
  - Myanmar (Burma)
  - Vietnam
  - Philippines
  - Ethiopia
  - Laos
  - Somalia
County of Occurrence

- **Top 3:**
  - Sedgwick
  - Johnson
  - Wyandotte

- **Other Counties:**
  - Shawnee
  - Finney
  - Geary
  - Ford
  - Douglas
  - Riley
Population Density Classification

Map of Kansas by County, 2015

Population Density Classification

- KDHE Classifications:
  - 1) Frontier (<6.0 ppsm)
  - 2) Rural (6.0-19.9 ppsm)
  - 3) Densely-Settled Rural (20.0-39.9 ppsm)
  - 4) Semi-Urban (40.0-149.9 ppsm)
  - 5) Urban (150+ ppsm)

*Population Density by Classification* (persons per square mile)

- Frontier (less than 6.0 ppsm)
- Rural (6.0 - 19.9 ppsm)
- Densely-settled Rural (20.0 - 39.9 ppsm)
- Semi-Urban (40.0 - 149.9 ppsm)
- Urban (150.0 ppsm or more)

* Kansas Department of Health and Environment classifications.
Risk Factor Visualization
Risk Factor Visualization (Continued)
Risk Factor Visualization (Continued)
Observations:

- Active TB in Kansas
  - Greater proportion of foreign-born cases
- When a foreign-born immigrant, traveler, student, or refugee arrives in the U.S. from a TB high-burden country, they have a significantly higher rate of developing active TB than those who are born in the U.S.

- TB drug resistance cases
  - More commonly seen in foreign-born individuals
CDC WONDER Active TB Case Data (1993-2015)

- **CDC WONDER**
  - Online ad-hoc query system
  - Utilized for disseminating public health data and information for analysis
  - WONDER’s Online Tuberculosis Information System (OTIS)
    - Kansas and USA active TB data from years 1993-2015
Question Formulation / Testing:

**QUESTIONS:**

1) Is the relative proportion of foreign-born cases of active TB greater in Kansas than the true proportion or overall burden of foreign-born cases?

2) Is country of birth (U.S. vs foreign-born status) independent of multi-drug resistance?

3) Is TB therapy administration method (self-administered vs. DOT vs. both) independent of completion of therapy in Kansas TB cases?

**TESTING:**

Test 1 – A one-sample Z-test to compare proportions

Tests 2 & 3 – Chi-square tests to test independence of categorical variables with associated odds ratio calculations.
Test 1 (One-Sample Z-test for Proportions):

- **Question:** Is the relative proportion of foreign-born cases of TB greater in Kansas than the true proportion or overall burden of foreign-born cases (proportion of foreign-born cases in the U.S.)?

- **$H_0$:** $\mu_{KS} \leq \mu$, (where $\mu$ represents the true proportion of active TB Cases that are foreign-born)

- **$H_a$:** $\mu_{KS} > \mu$

- **Significance Level:** $\alpha = 0.05$

- **Decision Rule:** Reject $H_0$ if $Z >$ Critical Value (1.645).

- **Test Statistic:** $n = 1471$

  - $\hat{p} = \frac{\text{# of Foreign-Born Cases of Active TB in KS}}{\text{Total # of Active TB Cases in KS}} = \frac{764}{1471} = 0.5194$

  - $p_0 = \frac{\text{# of Foreign-Born Cases of Active TB in the U.S.}}{\text{Total # of Active TB Cases in the U.S.}} = \frac{169,127}{351,029} = 0.4818$

  - $Z = \frac{\hat{p} - p_0}{\sqrt{\frac{p_0(1-p_0)}{n}}} = \frac{0.5194 - 0.4818}{\sqrt{\frac{0.4818(1-0.4818)}{1471}}} = 2.8861 > 1.645$ (Critical Value)

  - From Standard Normal Table: $P(Z \leq 2.8861) = \Phi(2.9) = 0.9984$

  - $P$-Value: $1 - \Phi(2.9) = 1 - 0.9984 = 0.0016$
Test 1 (Continued):

- **Decision:** Reject $H_0$ in favor of $H_a$.
- **Conclusion:** The proportion of active TB cases that are foreign-born is greater in Kansas than the proportion of active TB cases that are foreign-born in the U.S (0.4818). (P-Value: 0.001962)
Test 2 (Chi-Square Test of Independence):

- **Question:** Is U.S./foreign-born status independent of multi-drug resistance?
- **$H_0$:** U.S./Foreign-Born Status is independent of Multi-Drug Resistance Status
- **$H_a$:** U.S./Foreign-Born Status is not independent of Multi-Drug Resistance Status
- **Significance Level:** $\alpha = 0.05$
- **Decision Rule:** Reject $H_0$ if $\chi^2 >$ Critical Value
- **Test Statistic:** $df = (r-1)(c-1) = (2-1)(2-1) = 1$
  - From $\chi^2$ Distribution Table: $\chi^2_{(df=1,\alpha=0.05)} = 3.84$ (Critical Value)
  - $\chi^2 = \sum \frac{(|\text{Observed}-\text{Expected}|-0.5)^2}{\text{Expected}}$ (With Yates’ Continuity Correction)
  - $= \frac{(13.5-7.4866-0.5)^2}{7.5} + \frac{(586.5-592.5134-0.5)^2}{592.5} + \frac{(0.5-6.5134-0.5)^2}{6.5} + \frac{(521.5-515.4866-0.5)^2}{515.5}$
  - $= 8.84 > 3.84$ (Critical Value)
Test 2 (Continued):

- **Decision:** Reject $H_0$ in favor of $H_a$.
- **Conclusion:** **U.S./foreign-born status is not independent of MDR status** ($P$-Value: 0.002951).
ODDS RATIO CALCULATION (Test 2):

- Odds of Risk Factor (MDR-TB) in Foreign Born: 13.5/586.5 = 0.2302
- Odds of Risk Factor (Foreign-Born) in Controls (Not MDR-TB): 0.5/521.5 = 0.0009588
- Odds Ratio: (13.5/586.5) / (0.5/521.5) = 24.0077

Conclusion: The foreign-born TB cases in Kansas were **24 times** more likely to be MDR-TB cases than U.S.-born TB cases in Kansas.
Test 3 (Chi-Square Test of Independence):

- **Question:** Is TB therapy administration method (self-administered vs. DOT vs. both) independent of completion of therapy in cases of active TB in Kansas?
- **$H_0$:** Treatment Administration Method is independent of Therapy Completion Status.
- **$H_a$:** Treatment Administration Method is not independent of Therapy Completion Status.
- **Significance Level:** $\alpha = 0.05$
- **Decision Rule:** Reject $H_0$ if $\chi^2 > \text{Critical Value}$
- **Test Statistic:** $df = (r-1)(c-1) = (3-1)(2-1) = 2$
  - From $\chi^2$ Distribution Table: $\chi^2_{(df=2, \alpha=0.05)} = 5.9915$ (Critical Value)
  - $\chi^2 = \sum \frac{(\text{Observed} - \text{Expected})^2}{\text{Expected}} = \frac{(812-799.45)^2}{799.45} + \frac{(71-77.48)^2}{77.48} + \frac{(86-92.07)^2}{92.07} + \frac{(65-77.55)^2}{77.55} + \frac{(14-7.52)^2}{7.52} + \frac{(15-8.93)^2}{8.93}$
  - $= 12.887 > 5.9915$ (Critical Value)
Test 3 (Continued):

- **Decision:** Reject $H_0$ in favor of $H_a$.

- **Conclusion:** Treatment method is not independent of therapy completion (P-Value: 0.001591).
Test 3 (Odds Ratio Calculation):

**ODDS RATIO CALCULATION (Test 3):**

- Odds of Therapy Completion in Cases with some sort of DOT: \( \frac{898}{80} = 11.2250 \)
- Odds of Therapy Completion in Cases without any sort of DOT: \( \frac{71}{14} = 5.0714 \)
- **Odds Ratio:** \( \frac{898/80}{71/14} = 2.2134 \)

**Conclusion:** The active TB cases in Kansas who had some sort of DOT were **2.2 times** more likely to finish therapy within 1 year than those who only self-administered their TB therapy.
Results, Conclusions, and Discussion:

- **MPH Competency (Social and Behavioral Sciences):**
  - **Promoting Cultural Sensitivity**
    - TB is a highly stigmatizing disease in many cultures
    - Promoted cultural awareness for health care workers utilizing the TB manual
      - CDC’s Promoting Cultural Sensitivity series
  - **Google Translate**
    - Better health communication and treatment adherence by foreign-born individuals
      - May reduce foreign-born cases of TB in Kansas
      - Mitigate state spending on TB treatment
  - **E-DOT**
    - Some form of DOT is better than none
Additional Data Collection via SurveyMonkey

- **SurveyMonkey Online Survey**
  - Saline County Health Department Staff
  - Assess general knowledge and gain feedback
    - Video-communication and translation services
Regarding e-DOT:

- **7/19 (37%)**
  - Never used video-communication before
- **After introduction to DOT, associated time & monetary costs, and e-DOT,**
  - **17/19 (89.5%)**
    - Thought that e-DOT would be a good way of providing remote therapy
    - Concerns of 2 respondents:
      - 1) Manipulation of e-DOT observation
      - 2) Lost client-caregiver connection and other observations without direct contact

e-DOT (Electronic DOT) is a relatively new, CDC-recommended implementation plan for DOT. (Using video chat via smartphones, tablets, or webcam computers to directly observe the patient swallowing the medication and to provide education. The patient would still be met with physically on occasion for check ups.) (Assume that you and your patient know how to use Skype, FaceTime, etc...) In real practice, would you think that implementation of this plan would be a good way of providing DOT care to these patients? (The alternative would be to go out to see some of these patients daily to observe them taking their medicine physically.)
Regardin Google Translate:

- **17/19 (90%)**
  - Familiar with using a smartphone to seek answers to questions

- **11/19 (58%)**
  - Familiar with Google Translate before survey

- **16/19 (84%)**
  - Found the instructions “easy and useful” to follow/implement
3.2.4) Producing the Product:

**MANUAL CUSTOMIZATIONS:**

- Use of graphics and visually pleasing tables to accompany procedures
  - (e.g. Tuberculin Skin Test section)
- Electronic DOT (e-DOT) Implementation
- Promoting Cultural Sensitivity
- Translator Services & Google Translate Implementation
- Other Relevant SCHD/KS Customizations
  - (e.g. KS State Statutes, KS TB Infection Control Measures, SCHD TB forms).
SCHD TB Protocol Manual Navigation:

Part 1: An Introduction to Tuberculosis Control
- I. Introduction
- II. Effective TB Control Programs
- III. Pathogenesis of Tuberculosis

Part 2: Latent Tuberculosis Infection Management
- IV. Targeted Tuberculin Skin Testing & IGRA
  - CUSTOM: Graphics accompanying procedures (e.g. Tuberculin Skin Test section)
- V. Treatment of Latent TB Infection
Part 3: Active Tuberculosis Disease Management

- VI. Diagnosis of Tuberculosis
- VII. Treatment of Tuberculosis
  - CUSTOM: Colorful TB Treatment Regimen Tables

Part 4: Adherence Promoting Strategies

- VIII. Promoting Treatment Adherence
  - CUSTOM: Electronic DOT (e-DOT) Implementation Instructions
- IX. Managing Non-Adherence
  - CUSTOM: Kansas State Statutes
- X. Promoting Cultural Sensitivity
  - CUSTOM: Promoting Cultural Sensitivity (CDC series adaptation)
  - CUSTOM: Translator Services & Google Translate Implementation Instructions

Part 5: Contact Investigations & Infection Control
- XI. Contact Investigations
- XII. Infection Control
- CUSTOM: Kansas TB Infection Control Measures

Part 6: References & Appendices
- XIII. References
- XIV. Appendices
- CUSTOM: SCHD TB Forms (SCHD Treatment Agreement Forms, SCHD Medication Administration Record (MAR) Form, SCHD Contact Investigation Form, & KDHE Interpreter/Translator Vendor List)
3.2.5) External Review:

- Saline County Health Department Communicable Disease / TB Program Manager
  - Maria Shoulty, RN

- Stanford University, School of Medicine (Department of Radiology) Resident Physician
  - Joseph Tseng, MD

- MPH Report Review:
  - Robert Larson, PhD (KSU CVM)
3.3) Results/Discussion

3.3.1) DOCUMENT PRODUCED
3.3.2) POTENTIAL AREAS OF IMPROVEMENT
3.3.1) Document Produced

- Saline County Health Department Guidelines for the Prevention, Diagnosis, and Treatment of Tuberculosis (2017) (written and adapted for use by the Saline County Health Department and other local health departments in Kansas)
3.3.2) Potential Areas of Improvement

- **Areas of Potential Improvement**
  - 1) More picture graphics to aid in procedural instructions
    - e.g. Contact Investigation and Infection Control sections
  - 2) Additional information on Second-Line TB drugs
    - Ways to implement anti-TB drugs in the case of MDR-TB or XDR-TB
References


graphicguides/burma.pdf

graphicguides/china.pdf
References (Continued)


24) CDC. “Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug Resistant Tuberculosis.” MMWR October 25, 2013/Vol62/No. RR-14. 
https://www.cdc.gov/mmwr/pdf/rr/rr6209a1_e.pdf

https://www.cdc.gov/tb/publications/factsheets/testing/skintestresults.htm

https://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf

https://www.cdc.gov/tb/topic/testing/testingduringsregnancy.htm

https://www.cdc.gov/tb/topic/testing/testingbcgvaccinated.htm


https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm

https://www.cdc.gov/mmwr/pdf/rr/rr3918a1_e.pdf
References (Continued)


45) National TB Center (Heartland). “Tuberculosis Medication Drug and Food Interactions.” The University of Texas Health Science Center at Tyler.


60) All images from powerpoint courtesy of Google Images
Special Thanks...

- **Family:**
  - Tommy, Julie, & Esther Yang and Joseph Tseng, MD

- **Saline County Health Department Staff:**
  - Jason Tiller, MS *(Director & MPH Mentor)*
  - Maria Shoultys, RN *(Communicable Disease / TB Program Manager)*

- **MPH Committee:**
  - Robert Larson, PhD, DVM *(KSU College of Veterinary Medicine)*
  - Nancy Muturi, PhD *(KSU A.Q. Miller School of Journalism and Mass Communications)*
  - Wei-Wen Hsu, PhD *(KSU Department of Statistics)*

- **MPH Staff:**
  - Ellyn Mulcahy, PhD, MPH *(Director, KSU Master of Public Health Program)*
  - Barta Stevenson *(Program Assistant, Master of Public Health Program)*
Thank you!

Questions?